Pomdoctor H1 2026 net loss widens to RMB 238.17 mln as share-based compensation rises
Pomdoctor said net revenue rose 6% to RMB 185 million for the six months ended June 30, 2026, while net loss widened to RMB 238.17 million on RMB 215.7 million of share-based compensation tied to marketing, administrative and R&D services.
Story updates
08:06:48 PM UTC
SquawkNews
Pomdoctor posted a net loss of RMB 238.17 million for the six months ended June 30, 2026. Net revenues rose 6% to RMB 185 million in the six months ended June 30, 2026. Loss from operations widened to RMB 233.33 million in the period. * Sales and marketing expenses surged to RMB 76.4 million, while research and development expenses jumped to RMB 106.27 million. It reported a going-concern warning, citing a RMB 137.2 million working capital deficit at June 30, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pomdoctor Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-104640), on September 29, 2026, and is solely responsible for the information contained therein. (C)